Author  
Place of duty  
Title   급성 백혈병 환자에서 항암제 치료로 유발되는 오심과 구토에 대한 Ondansetron 의 효과 ( Effects of Ondansetron in the Prevention of Nausea and Vomiting Associated with Chemotherapy in Acute Myelocytin Leukemia )
Publicationinfo   1992 Jan; 024(02): 288-293.
Key_word   Chemotherapy, Ondansetron
Full-Text  
Abstract   Chemotherapy induced nausea and vomiting continues to be a significant problem in the care of patients receiving cancer chemotherapy. Existing antiemetic regimens such as high- dose metoclopramide have demonstrated clinical effecacy. Originally, the antiemetic effect of metoclopramide was thought to be mediated by dopamine receptor blockade and so produced adverse events like as extrapyramidal reactions. Ondansetron(GR 38032 F)is a selective antagonist of serotonin subtype 3 receptors, and is a potent antiemetic agent when used in patients receiving cancer chemotherapy. Ondansetron is at least as effective as metoclopramide in the management of 6-TG/Ara-c/ Daunorubicin induced emesis in Acute myelocytic leukemia 1) The antiemetic efficacy of ondansetron showed eleven(73.3%) patients had a compete response to therapy and threeQ0%) patients had a major response. There is one patient who had<5 emetic episodes(minor response) but no patients who had treatment failure in 15 AML patients 2) The adverse events of ondansetron showed two patients had headache and one patient had a loose stools. Elevation in serum aspartate aminotransferase(AST) and ALT ocurred in three patients, but in patients with normal baseline enzyme levels, AST values increased to less than twice the upper limit of normal valuses.
저 자   민우성(Woo Sung Min),진종률(Jong Youl Jin),한치화(Chi Wha Han),박종원(Chong Won Park),김춘추(Choon Choo Kim),김동집(Dong Jip Kim)